Brought to you by 
Merrimack IPO nets $95.6mm
04 Apr 2012
Executive Summary
Cancer drug developer Merrimack Pharmaceuticals Inc. has netted $95.6mm through its initial public offering by selling 14.3mm common shares at $7. The company originally filed in August 2011 and announced in January 2012 that it hoped to sell 16.67mm shares between $8-10 apiece. Shortly thereafter, there was speculation that Merrimack would postpone or withdraw its filing due to market conditions, but an accelerated S1 approval led the company to a successful pricing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merrimack IPO nets $95.6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice